N/A
N=54
Metacognitive and Insight Therapy for Persons With Schizophrenia (RCT MERIT)
Diagnosis of Schizophrenia Spectrum Disorders
Bottom Line
View on ClinicalTrials.gov: NCT03427580 ↗Enrolled (actual)
54
Serious AEs
0.0%
Results posted
Mar 2025
Primary outcome: Primary: Metacognition Assessment Scale-Abbreviated (MAS-A) — 11.53; 14.22; 14.22; 14.25 score on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- MERIT (Behavioral)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- Bar-Ilan University, Israel
- Primary completion
- Mar 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Metacognition Assessment Scale-Abbreviated (MAS-A) |
11.53; 14.22; 14.22; 14.25 | — |
Summary
People with schizophrenia spectrum disorders are faced with significant metacognitive impairments that include difficulties in their ability to form complex representations of the self and others. These impairments are associated with increased symptoms, impaired subjective self-experiences, and lower social functioning. As a result, interventions that enhance metacognitive capacity have been recently developed and explored. One of these interventions is Metacognitive Reflection and Insight Therapy (MERIT; Lysaker et al., 2014). MERIT is an integrative model of psychotherapy that seeks to promote holistic metacognitive capacity and consequently increase a positive sense of agency and sense of meaning in life among clients with schizophrenia. Several case studies (including in Bar-Ilan's community clinic), as well as a recent pilot study, showed increased metacognitive abilities and a decrease in symptoms following MERIT. The current study will explore both the effectiveness and the change mechanisms that underlie MERIT interventon among clients diagnosed with schizophrenia spectrum disorders, via both pre- and post-measures of the intervention's outcome and session-by-session estimations of the therapeutic process.
Eligibility Criteria
Inclusion Criteria
- Diagnosis of schizophrenia spectrum disorders
- Ability to provide informed consent
- Ability to read and write in Hebrew
Exclusion Criteria
- No co-morbid nuerological condition
- No hospitalization in the last 6 months
Data sourced from ClinicalTrials.gov (NCT03427580). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.